FDA's vac­cine ad­comm to re­view first fe­cal trans­plant to treat C. dif­fi­cile in­fec­tions

Back in 2018, Swiss drug­mak­er Fer­ring Phar­ma­ceu­ti­cals made a big bet on Min­neso­ta-based Re­bi­otix, buy­ing up the com­pa­ny for its ex­per­i­men­tal poop-based drug im­plant to treat an in­fec­tion caused by C. dif­fi­cile, a po­ten­tial­ly dan­ger­ous bac­te­ria, in a new way.

Four years lat­er, Fer­ring’s fe­cal mi­cro­bio­ta trans­plant, dubbed RBX2660 or Re­by­ota, will face the FDA’s ad­comm of out­side vac­cine ex­perts on Sept. 22, de­bat­ing whether the agency should li­cense the trans­plant as a treat­ment for adults fol­low­ing an­tibi­ot­ic treat­ment for re­cur­rent C. dif­fi­cile in­fec­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.